About: Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime
Creator	Roberts, Jason Avedissian, Sean Kiel, J Lipman, Jeffrey Liu, Jiajun Neely, Michael Patrick, · Rhodes, Nathaniel Scheetz, Marc Sime, ·
Source	PMC
abstract	BACKGROUND AND OBJECTIVE: Understanding pharmacokinetic disposition of cefepime, a β-lactam antibiotic, is crucial for developing regimens to achieve optimal exposure and improved clinical outcomes. This study sought to develop and evaluate a unified population pharmacokinetic model in both pediatric and adult patients receiving cefepime treatment. METHODS: Multiple physiologically relevant models were fit to pediatric and adult subject data. To evaluate the final model performance, a withheld group of 12 pediatric patients and two separate adult populations were assessed. RESULTS: Seventy subjects with a total of 604 cefepime concentrations were included in this study. All adults (n = 34) on average weighed 82.7 kg and displayed a mean creatinine clearance of 106.7 mL/min. All pediatric subjects (n = 36) had mean weight and creatinine clearance of 16.0 kg and 195.6 mL/min, respectively. A covariate-adjusted two-compartment model described the observed concentrations well (population model R(2), 87.0%; Bayesian model R(2), 96.5%). In the evaluation subsets, the model performed similarly well (population R(2), 84.0%; Bayesian R(2), 90.2%). CONCLUSION: The identified model serves well for population dosing and as a Bayesian prior for precision dosing. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40262-020-00873-3) contains supplementary material, which is available to authorized users.
has issue date	2020-03-05(xsd:dateTime)
bibo:doi	10.1007/s40262-020-00873-3
bibo:pmid	32140940
has license	no-cc
sha1sum (hex)	74e06fdcd5eb6190e5dd4b7833d0a7fc9757197d
schema:url	https://doi.org/10.1007/s40262-020-00873-3
resource representing a document's title	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime
has PubMed Central identifier	PMC7222999
has PubMed identifier	32140940
schema:publication	Clin Pharmacokinet
resource representing a document's body	covid:74e06fdcd5eb6190e5dd4b7833d0a7fc9757197d#body_text
is schema:about of	named entity 'model' named entity 'subjects' named entity 'pediatric' named entity 'evaluation' named entity 'creatinine clearance' named entity 'group' named entity 'Population' named entity 'study' named entity 'dosing' named entity 'observed' named entity 'adult' named entity 'Bayesian' named entity 'population model' named entity 'optimal' named entity 'patients' named entity 'model' named entity 'evaluate' named entity 'creatinine clearance' named entity 'models' named entity 'pediatric' named entity '16.0' named entity 'covariate' named entity 'allometric scaling' named entity 'MICs' named entity 'infusion' named entity 'weighted prediction' named entity 'cefepime' named entity 'bloodstream infections' named entity 'adaptive grid' named entity 'best-fit' named entity 'steady state' named entity 'Enterobacteriaceae' named entity 'PTA' named entity 'antimicrobial agents' named entity 'variance-covariance matrix' named entity 'cefepime' named entity 'MICs' named entity 'MIC' named entity 'hematologic malignancies' named entity 'therapeutic drug monitoring' named entity 'clinical outcomes' named entity 'PTA' named entity 'pneumonia' named entity 'Covariate' named entity 'PTA' named entity '1, 2' named entity 'cefepime' named entity 'β-lactam antibiotics' named entity 'MICs' named entity 'renal function' named entity 'elimination rate constant' named entity 'log-likelihood' named entity 'Goodness of fit' named entity 'Goodness-of-fit' named entity 'central compartment' named entity 'critical illness' named entity 'Clinical and Laboratory Standards Institute' named entity 'maximum plasma concentration' named entity 'National Health Institute' named entity 'plasma' named entity 'clinical outcomes' named entity 'Precision medicine' named entity 'steady state' named entity 'differential equations' named entity 'cefepime' named entity 'cefepime' named entity 'predictive checks' named entity 'Cefepime' named entity 'organ dysfunction' named entity 'sepsis' named entity 'Cefepime' named entity 'Gram-negative'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software